Поле DC | Значение | Язык |
dc.contributor.author | Avdeeva, N. V. | - |
dc.contributor.author | Kulikov, A. L. | - |
dc.contributor.author | Pokrovskii, M. V. | - |
dc.contributor.author | Avtina, T. V. | - |
dc.date.accessioned | 2022-04-29T08:56:27Z | - |
dc.date.available | 2022-04-29T08:56:27Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Pharmacokinetic studies of new antiparkinsonian drug Rapitalam / N. V. Avdeeva [et al.] // Research result: pharmacology and clinical pharmacology. - 2016. - Vol. 2, № 4.- P. 3-8. - Doi: 10.18413/2500-235X-201 6-2-4-3-8. - Refer.: p. 7-8. | ru |
dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46520 | - |
dc.description.abstract | The aim of this study was to investigate the pharmacokinetic parameters of the mGluR4 receptor blocker Rapitalam on rabbits. There was developed the method of the quantitative determination of Rapitalam in the blood plasma of rabbits using high performance liquid chromatography with tandem mass spectrometric detection. The study was performed on 12 rabbits (males, weighing between 3,300 to 3,500 g). In intragastric dosing of the substance was administered using a gastric tube in the form of suspension in water 0.9 mg/ml, 9 mg/ml, and 90 mg/ml at a dose of 0.3 mg/kg, 3 mg/kg and 30 mg/kg. The main pharmacokinetic parameters of the substance was established on rabbits that allow you to optimize the future use of it's as a potential drug for the treatment of Parkinson's disease | ru |
dc.language.iso | en | ru |
dc.subject | medicine | ru |
dc.subject | pharmacology | ru |
dc.subject | pharmacokinetics | ru |
dc.subject | Rapitalam | ru |
dc.subject | Parkinson's disease | ru |
dc.subject | the blood plasma of rabbits | ru |
dc.subject | high performance liquid chromatography | ru |
dc.subject | metabotropic glutamate receptors | ru |
dc.title | Pharmacokinetic studies of new antiparkinsonian drug Rapitalam | ru |
dc.type | Article | ru |
Располагается в коллекциях: | Vol. 2, № 4
|